Guided by various clinical trials for colorectal cancer [29–32], we selected and tested combinations of BRAF/EGFR, BRAF/MEK, MEK/WNT, and BRAF/WNT inhibitors at their IC50 concentrations against CRC2 spheroids. The gene discussed is MAP2K7; the disease is colorectal cancer.